Feasibilitystudy of leprosy active case findings by contact tracing and the administration of a single dose of rifampicin as post-exposure prophylaxis in Senegal - LPEP-Senegal

Deutsche Lepra und Tuberkulosehilfe e.V.0 个研究点目标入组 14,000 人开始时间: 2020年10月20日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Anyone usually residing in the villages reporting leprosy cases in the last five years and are considered for active screening and aged 2 years or over regardless of their sex, social, ethnic or religious affiliation.

•- Refusal to give informed consent for screening or for the disclosure of the diagnosis to other members of his family
•- Refusal to give informed consent for PEP
•- Age <2 years
•- New leprosy confirmed (cases should be put on MDT if they have not yet received MDT) or suspected, until the disease is ruled out
•- overt signs and / or symptoms of tuberculosis (patients with any of the following symptoms should be referred to a tuberculosis diagnostic center for screening for the following symptoms: cough for more than two weeks, night sweats, unexplained fever , weightloss)
•- Treatment with rifampicin for a given reason within the last two years (e.g. for treatment of tuberculosis or leprosy, or as contact with another index case)
•- Pregnancy (PEP can be given after childbirth)
•- History of liver problems (eg jaundice) or kidney problems
•- Allergy to rifampicin

发起方

Deutsche Lepra und Tuberkulosehilfe e.V.